Hot Features
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive ... Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.015 | 8.82352941176 | 0.17 | 0.245 | 0.16475 | 100919049 | 0.19901648 | DE |
| 4 | -0.005 | -2.63157894737 | 0.19 | 0.245 | 0.1535 | 42047504 | 0.19200362 | DE |
| 12 | -0.04 | -17.7777777778 | 0.225 | 0.245 | 0.1535 | 32436550 | 0.18679644 | DE |
| 26 | -0.075 | -28.8461538462 | 0.26 | 0.39 | 0.1535 | 34692119 | 0.22145395 | DE |
| 52 | 0.075 | 68.1818181818 | 0.11 | 0.55 | 0.0725 | 40754310 | 0.21096217 | DE |
| 156 | -0.065 | -26 | 0.25 | 0.55 | 0.04 | 27302025 | 0.16060573 | DE |
| 260 | -1.915 | -91.1904761905 | 2.1 | 2.35 | 0.04 | 18352906 | 0.22732434 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.